Loading...
Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer
BACKGROUNDS: Despite the clinical success of taxanes, they still have limitations, such as chemoresistance. To overcome the limitations of paclitaxel, genetic alterations and targeting effects of altered genes were observed in paclitaxel-resistant cancer. Because paclitaxel-resistant cancer shows hi...
Na minha lista:
| Udgivet i: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6515847/ https://ncbi.nlm.nih.gov/pubmed/31156720 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919846375 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|